Observational study of 181 patients with advanced disease requiring oxygen showing no benefit for HCQ. Power of study appears too low to support conclusions [1].
None of the 15 patients receiving HCQ+AZ were transferred to intensive care or died compared to 23% overall.
Mahévas et al., 5/14/2020, retrospective, France, Europe, peer-reviewed, 34 authors.
risk of death, 20.0% higher, RR 1.20, p = 0.75, treatment 9 of 84 (10.7%), control 8 of 89 (9.0%), adjusted per study.
Effect extraction follows
pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.